# Title

 Food and Drugs. PART 207â€”REQUIREMENTS FOR FOREIGN AND DOMESTIC ESTABLISHMENT REGISTRATION AND LISTING FOR HUMAN DRUGS, INCLUDING DRUGS THAT ARE REGULATED UNDER A BIOLOGICS LICENSE APPLICATION, AND ANIMAL DRUGS, AND THE NATIONAL DRUG CODE


# ID

 CFR-2018-title21-vol4.Pt. 207


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                     |
|:------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['more than', 'no later than', 'before', 'after', 'prior to', 'minimum', 'at least', 'within']                                                                                                             |
| Duration    | ['2.0 year', '30.0 day', '3.0 day', '5.0 day']                                                                                                                                                             |
| Condition   | ['subject to', 'if not', 'where', 'not subject to', 'when', 'provided that', 'unless', 'if']                                                                                                               |
| Entities    | ['U.S', 'Failure', 'United States', 'Relabel', 'Puerto Rico', 'Material', 'Bulk', 'Salvage', 'Salvager', 'Food', 'English', 'Establishment', 'Columbia', 'Drug', 'Manufacture', 'Agriculture', 'Domestic'] |
| Date        | ['2018-10-01', '2018-12-31', '2002-06-03', '2001-06-04', '2037-05-01', '2018-06-01', '1913-03-04']                                                                                                         |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                                |
|:--------------|:---------------------------------------------------------------------------------------------------------------------------------------|
| within        | repacker, relabeler, salvager, private label distributor, or establishment within any State or Territory of the United States,         |
| after         | assigned to the establishment, as identified by FDA, after  the establishment registration required in this part.                      |
| at least      | form (e.g., tablet, capsule, or solution) that contains at least one active pharmaceutical ingredient, generally, but not necessarily, |
| more than     | When operations are conducted at  more than one establishment and common ownership and control among                                   |
| no later than | (a) Registrants must register each domestic establishment  no later than 5 calendar days after beginning to manufacture, repack,       |
| after         | domestic establishment no later than 5 calendar days after beginning to manufacture, repack, relabel, or salvage a                     |
| before        | (b) Registrants must register each foreign establishment  before a drug or an animal feed bearing or                                   |
| no later than | Registrants must update their registration information  no later than 30 calendar days after: (1) Closing or selling                   |
| prior to      | of initial registration, if the initial registration occurs prior to  October 1.                                                       |
| within        | the information submitted under paragraph (c)(1)of this section within 30 calendar days after any change to that                       |
| after         | paragraph (c)(1)of this section within 30 calendar days after  any change to that information.                                         |
| before        | voluntarily reserve a proposed NDC for a drug, before the drug is listed, by submitting the following                                  |
| after         | for a drug when there is a change, after the drug is initially marketed, to any of                                                     |
| before        | was assigned to it as described in &#167;&#8201;207.33, before  marketing was discontinued.                                            |
| more than     | When operations are conducted at  more than one establishment, and common ownership and control exists                                 |
| after         | When,  after initial registration of an establishment, must drug listing                                                               |
| no later than | initial registration, drug listing information must be submitted no later than 3 calendar days after the initial registration of       |
| after         | be submitted no later than 3 calendar days after  the initial registration of the establishment.                                       |
| within        | Such advertisements must be submitted  within  30 calendar days after FDA's request.                                                   |
| after         | advertisements must be submitted within 30 calendar days after  FDA's request.                                                         |
| within        | Such advertisements must be submitted  within  30 calendar days after our request.                                                     |
| after         | advertisements must be submitted within 30 calendar days after  our request.                                                           |
| before        | (a) The NDC assigned to the drug immediately  before the drug is received by the registrant for                                        |
| minimum       | must review and update listing information at a minimum , as follows: (a) Registrants must provide listing                             |
| after         | been made since the previous annual registration update. after                                                                         |
| prior to      | every drug subject to listing under this part prior to commercial distribution and are encouraged to update listing                    |
| minimum       | content of labeling must be provided at a minimum  in the English language.                                                            |
| prior to      | granted a request for waiver of this requirement prior to the date on which submission of such information                             |
| after         | obtained under &#167;&#8201;207.33, &#167;&#8201;207.49, &#167;&#8201;207.53, &#167;&#8201;207.54, or &#167;&#8201;207.57. after       |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                               |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5.0 day    | (a) Registrants must register each domestic establishment no later than 5 calendar days after beginning to manufacture, repack, relabel, or salvage a drug or an animal feed bearing or containing a new animal drug at such establishment.                                           |
| 30.0 day   | Registrants must update their registration information no later than 30 calendar days after:                                                                                                                                                                                          |
|            |                       (1) Closing or selling an establishment;                                                                                                                                                                                                                        |
|            |                       (2) Changing an establishment's name or physical address; or                                                                                                                                                                                                    |
|            |                       (3) Changing the name, mailing address, telephone number, or email address of the official contact or the United States agent.                                                                                                                                  |
| 30.0 day   | (2) Each person who is assigned an NDC labeler code must update the information submitted under paragraph (c)(1)of this section within 30 calendar days after any change to that information.                                                                                         |
| 2.0 year   | (4) If the required information is submitted and the proposed NDC is properly formatted and not already assigned or reserved, FDA will reserve the proposed NDC for a period of 2 years from the date of submission.                                                                  |
| 2.0 year   | If the drug for which the proposed NDC is reserved is not listed in accordance with &#167;&#8201;207.49 or &#167;&#8201;207.53 during such 2-year period, the reservation of the proposed NDC will lapse.                                                                             |
| 3.0 day    | For each drug being manufactured, repacked, relabeled, or salvaged for commercial distribution at an establishment at the time of initial registration, drug listing information must be submitted no later than 3 calendar days after the initial registration of the establishment. |
| 30.0 day   | Such advertisements must be submitted within 30 calendar days after FDA's request.                                                                                                                                                                                                    |
| 30.0 day   | Such advertisements must be submitted within 30 calendar days after our request.                                                                                                                                                                                                      |


## Condition

| Condition      | Context                                                                                                                                                          |
|:---------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| if not         | apply to the terms used in this part, if not  otherwise defined in this section.                                                                                 |
| subject to     | means: (1) For human prescription drugs that are subject to section 505 of the Federal Food, Drug, and                                                           |
| not subject to | (2) For human prescription drugs that are  not subject to section 505 of the Federal Food, Drug, and                                                             |
| subject to     | (including, but not limited to, drugs that are subject to section 512 of the Federal Food, Drug, and                                                             |
| when           | purposes of registration and listing under this part, when used to modify the term &#8220;registrant,&#8221; &#8220;manufacturer,&#8221; &#8220;repacker,&#8221; |
| when           | or offered for import into the United States. when                                                                                                               |
| when           | or offered for import into the United States. when                                                                                                               |
| subject to     | Repackers, relabelers, and salvagers are  subject to the provisions of this part that are applicable                                                             |
| not subject to | applicable to repackers, relabelers, and salvagers, but are not subject to the provisions of this part that are applicable                                       |
| where          | is manufacturing, repacking, relabeling, and salvaging drugs and where  those operations are performed.                                                          |
| subject to     | These establishments are  subject to the requirements of this part unless they are                                                                               |
| unless         | are subject to the requirements of this part unless they are required to register and list such                                                                  |
| unless         | or process human whole blood and blood products unless the establishment also manufactures, repacks, or relabels other                                           |
| unless         | exempt from registration and listing under this part unless FDA determines that drug establishment registration and listing                                      |
| where          | feeds, as defined in &#167;&#8201;558.5 of this chapter, where the specifications and/or formulas are not published and                                          |
| provided that  | 832 (21 U.S.C. 151 et seq.)),  provided that this exemption from registration applies only to the                                                                |
| unless         | establishment registration and listing requirements of this part unless  exempt under this section or                                                            |
| if             | this section do not apply to such persons if  they:                                                                                                              |
| subject to     | &#167;&#8201;600.3(u) of this chapter) a human biological product subject to licensing under section 351 of the Public Health                                    |
| unless         | or offered for import into the United States. unless                                                                                                             |
| if             | information submitted by a private label distributor only if it is acting as an authorized agent for                                                             |
| if             | of the owner or operator of each establishment; if  a partnership, the name of each partner;                                                                     |
| if             | of the owner or operator of each establishment; if  a partnership, the name of each partner;                                                                     |
| if             | of the owner or operator of each establishment; if  a partnership, the name of each partner;                                                                     |
| subject to     | and (h) Additionally, with respect to foreign establishments subject to registration, the name, mailing address, telephone number, and                           |
| if             | December 31 of the year of initial registration, if  the initial registration occurs prior to October 1.                                                         |
| if             | occurred since the last registration, registrants must cert if y that no changes have occurred.                                                                  |
| subject to     | Each finished drug product or unfinished drug  subject to the listing requirements of this part must have                                                        |
| if             | of 10 or 11 digits (5-3-2 or 6-3-2). if                                                                                                                          |
| if             | a total NDC length of 10 digits (4-4-2). if                                                                                                                      |
| if             | Director may be used for the following HCT/Ps if they are minimally manipulated: Hematopoietic stem/progenitor cells derived                                     |
| subject to     | relabeling, or private label distribution of a drug subject to listing under this part must apply for an                                                         |
| when           | is an NDC proposed for assignment by FDA, when is an NDC assigned by FDA, and how                                                                                |
| when           | An NDC is proposed for assignment by FDA when it is submitted for the first time with                                                                            |
| if             | (ii) In addition,  if a drug is distributed under the trade name                                                                                                 |
| if             | section and is not reserved for a d if ferent drug or was not previously assigned to                                                                             |
| when           | FDA will assign the NDC to a drug when it receives listing information required for that drug                                                                    |
| if             | of 2 years from the date of submission. if                                                                                                                       |
| unless         | (d) of this section must be submitted electronically unless  FDA grants a waiver under &#167;&#8201;207.65.                                                      |
| when           | a new and unique NDC for a drug when there is a change, after the drug is                                                                                        |
| when           | new NDC must include a new product code when there is a change to any of the                                                                                     |
| if             | (1) The drug's established name or proprietary name, if  any;                                                                                                    |
| when           | existing product code in NDCs assigned by FDA. when                                                                                                              |
| if             | size or type, including the immediate unit-of-use container, if any, the proposed new NDC must include only                                                      |
| unless         | package code and retain the existing product code unless all available package codes have already been combined                                                  |
| if             | A product may be deemed to be misbranded if an NDC is used: (1) To represent a                                                                                   |
| not subject to | a drug; or (3) On products that are not subject to parts 207, 607 of this chapter, or 1271                                                                       |
| if             | as described in &#167;&#8201;207.33, before marketing was discontinued. if                                                                                       |
| when           | paragraph include the registrant's labeler code, except that when the drug is manufactured for commercial distribution under                                     |
| if             | The listed drug's established name and proprietary name, if any; (4) The name and quantity of each                                                               |
| if             | The listed drug's established name and proprietary name, if any; (4) The name and quantity of each                                                               |
| if             | the Drug Master File or Veterinary Master File, if any, that describes the manufacture of the drug;                                                              |
| subject to     | the drug; (10) For each drug that is subject to the imprinting requirements of part 206 of this                                                                  |
| where          | name and Unique Facility Identifier of the establishment where the registrant who lists the drug manufactures it                                                 |
| where          | name and Unique Facility Identifier of the establishment where the registrant who lists the drug manufactures it                                                 |
| if             | under section 202 of the Controlled Substances Act, if applicable; (14) Advertisements: (i) A representative sampling of                                         |
| not subject to | advertisements for a human prescription drug that is not subject to section 505 of the Federal Food, Drug, and                                                   |
| if             | those advertisements described in &#167;&#8201;202.1(l)(1) of this chapter. if                                                                                   |
| not subject to | advertisements for a human prescription drug that is not subject to section 505 of the Federal Food, Drug, and                                                   |
| where          | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| subject to     | (A) For each human nonprescription drug  subject to section 505 of the Federal Food, Drug, and                                                                   |
| where          | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| not subject to | (B) For each human nonprescription drug  not subject to section 505 of the Federal Food, Drug, and                                                               |
| where          | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| subject to     | (A) For each animal drug that is  subject to section 512 of the Federal Food, Drug, and                                                                          |
| where          | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| where          | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| where          | that only one representative label need be submitted where differences exist only in the quantity of contents                                                    |
| if             | commercial distribution: (1) The drug's over-the-counter monograph reference, if any; and (2) The date on which the                                              |
| where          | name and Unique Facility Identifier of every establishment where repacking or relabeling is performed for the drug                                               |
| where          | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| subject to     | (i) For each human nonprescription drug  subject to section 505 of the Federal Food, Drug, and                                                                   |
| where          | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| not subject to | (ii) For each human nonprescription drug  not subject to section 505 of the Federal Food, Drug, and                                                              |
| where          | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| subject to     | (i) For each animal drug that is  subject to section 512 of the Federal Food, Drug, and                                                                          |
| where          | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| where          | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| where          | that only one representative label need be submitted where differences exist only in the quantity of contents                                                    |
| not subject to | advertisements for a human prescription drug that is not subject to section 505 of the Federal Food, Drug, and                                                   |
| if             | including advertisements described in &#167;&#8201;202.1(l)(1) of this chapter. if                                                                               |
| where          | name and Unique Facility Identifier for each establishment where  the registrant salvages the drug.                                                              |
| not subject to | basis for its belief that the drug is not subject to section 505 or 512 of the Federal Food,                                                                     |
| when           | What information must registrants submit  when  updating listing information and                                                                                 |
| subject to     | For each listed drug, certify that no changes subject to reporting under paragraph (b)(1)(iv) of this section have                                               |
| if             | part; or (2) For each listed drug, cert if y that no changes subject to reporting under                                                                          |
| subject to     | encouraged to submit listing information for every drug subject to listing under this part prior to commercial distribution                                      |
| unless         | transmitted to FDA electronically in accordance with &#167;&#8201;207.61(a) unless FDA has granted a request for waiver of                                       |
| if             | FDA will grant a waiver request  if FDA determines that the use of electronic means                                                                              |
| where          | and a U.S. telephone number and mailing address where  FDA can contact the registrant.                                                                           |
| if             | FDA may limit its duration and will spec if y terms of the waiver and provide information                                                                        |
| subject to     | Registrants  subject to the registration requirements of this part must designate                                                                                |
| subject to     | Registrants of foreign establishments  subject to this part must designate a single United States                                                                |
| where          | mailbox, answering machine or service, or other place where a person acting as the United States agent                                                           |
| if             | information and/or documents to the United States agent. if                                                                                                      |
| unless         | (12), &#167;&#8201;207.53(b) and (c), or &#167;&#8201;207.54(a) or (c). unless                                                                                   |
| not subject to | has been determined that a particular drug is not subject to section 505 or 512 of the Federal Food,                                                             |


## Entities

| Entities      | Context                                                                                                                   |
|:--------------|:--------------------------------------------------------------------------------------------------------------------------|
| Food          | Food  and Drugs.                                                                                                          |
| Bulk          | Bulk drug substance, as referenced in sections 503A(b)(1)(A) and                                                          |
| United States | neither imported nor offered for import into the United States .                                                          |
| Domestic      | Domestic for purposes of registration and listing under this                                                              |
| United States | establishment within any State or Territory of the United States , the District of Columbia, or the Commonwealth          |
| Columbia      | Territory of the United States, the District of Columbia , or the Commonwealth of Puerto Rico.                            |
| Puerto Rico   | the District of Columbia, or the Commonwealth of Puerto Rico .                                                            |
| Drug          | Drug , for the purposes of registration and listing                                                                       |
| Establishment | Establishment means a place of business under one management                                                              |
| United States | is imported or offered for import into the United States .                                                                |
| United States | is imported or offered for import into the United States .                                                                |
| United States | purposes of this part, a person in the United States that is an owner, consignee, or recipient, at                        |
| United States | purposes of this part, a person in the United States that is an owner, consignee, or recipient, at                        |
| Manufacture   | Manufacture means each step in the manufacture, preparation, propagation,                                                 |
| Manufacture   | Manufacture includes the making by chemical, physical, biological, or                                                     |
| Manufacture   | Manufacture includes manipulation, sampling, testing, or control procedures applied                                       |
| Material      | Material change means any change in any drug listing                                                                      |
| United States | a drug from a foreign country to the United States .                                                                      |
| United States | includes persons who send a drug to the United States by international mail or other private delivery service,            |
| Relabel       | Relabel means to change the existing label or labels                                                                      |
| Salvage       | Salvage means the act of segregating out those finished                                                                   |
| Salvager      | Salvager means a person who owns or operates an                                                                           |
| Bulk          | Bulk  drug substance.                                                                                                     |
| Bulk          | Bulk drug substance, as referenced in sections 503A(b)(1)(A) and                                                          |
| Establishment | Establishment registration information helps FDA identify who is manufacturing,                                           |
| Agriculture   | and unrevoked license issued by the Secretary of Agriculture under the animal virus-serum-toxin law of March 4,           |
| United States | are imported or offered for import into the United States must comply with the establishment registration and listing     |
| U.S           | trade zone and are re-exported without having entered U.S . commerce, or (2) Their drugs are imported                     |
| United States | is imported or offered for import into the United States .                                                                |
| United States | is imported or offered for import into the United States .                                                                |
| United States | email address must be provided for: (1) The United States agent, as provided in &#167;&#8201;207.69(b); (2) Each importer |
| United States | email address must be provided for: (1) The United States agent, as provided in &#167;&#8201;207.69(b); (2) Each importer |
| United States | email address must be provided for: (1) The United States agent, as provided in &#167;&#8201;207.69(b); (2) Each importer |
| United States | email address of the official contact or the United States  agent.                                                        |
| United States | A registrant, official contact, or  United States agent may notify FDA about a change of                                  |
| United States | A registrant, official contact, or  United States agent may notify FDA about a change of                                  |
| United States | A registrant, official contact, or  United States agent may notify FDA about a change of                                  |
| U.S           | (6) The dosage form; (7) The drug's approved U.S . application number, if any; (8) The drug                               |
| English       | (b)  English  language.                                                                                                   |
| Drug          | Drug establishment registration and drug listing information must be                                                      |
| English       | drug listing information must be provided in the English  language.                                                       |
| English       | must be provided at a minimum in the English  language.                                                                   |
| English       | submitted in that language along with an accurate English  translation.                                                   |
| U.S           | is not reasonable for the registrant and a U.S . telephone number and mailing address where FDA                           |
| U.S           | waiver requests must be sent to: SPL Coordinator, U.S .                                                                   |
| Food          | Food  and Drug Administration, 10903 New Hampshire Ave., Bldg.                                                            |
| United States | the requirements for an official contact and a United States  agent?                                                      |
| United States | (b)  United States  agent.                                                                                                |
| United States | subject to this part must designate a single United States  agent.                                                        |
| United States | The  United States agent must reside or maintain a place of                                                               |
| United States | The  United States agent must reside or maintain a place of                                                               |
| United States | The  United States agent must reside or maintain a place of                                                               |
| United States | The  United States agent is responsible for: (1) Reviewing, disseminating, routing,                                       |
| United States | The  United States agent is responsible for: (1) Reviewing, disseminating, routing,                                       |
| United States | The  United States agent is responsible for: (1) Reviewing, disseminating, routing,                                       |
| United States | FDA's providing information and/or documents to the  United States agent is equivalent to providing the same information  |
| Failure       | Failure  to comply with &#167;&#8201;207.37 may also constitute misbranding.                                              |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                      |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1913-03-04 | (h) Any manufacturer, repacker, relabeler, or salvager of a virus, serum, toxin, or analogous product intended for the treatment of domestic animals who holds an unsuspended and unrevoked license issued by the Secretary of Agriculture under the animal virus-serum-toxin law of March 4, 1913 (37 Stat. |
| 2018-10-01 | (1) The first review and update must occur during the period beginning on October 1 and ending December 31 of the year of initial registration, if the initial registration occurs prior to October 1.                                                                                                       |
| 2018-12-31 | (1) The first review and update must occur during the period beginning on October 1 and ending December 31 of the year of initial registration, if the initial registration occurs prior to October 1.                                                                                                       |
| 2018-10-01 | (1) The first review and update must occur during the period beginning on October 1 and ending December 31 of the year of initial registration, if the initial registration occurs prior to October 1.                                                                                                       |
| 2018-10-01 | Subsequent reviews and updates must occur annually, during the period beginning on October 1 and ending December 31 of each calendar year.                                                                                                                                                                   |
| 2018-12-31 | Subsequent reviews and updates must occur annually, during the period beginning on October 1 and ending December 31 of each calendar year.                                                                                                                                                                   |
| 2001-06-04 | (2) The following combinations of labeler code, product code and package code character lengths are permissible:                                                                                                                                                                                             |
|            |                       (i) If a labeler code is either 5 or 6 digits in length, it may be combined with:                                                                                                                                                                                                      |
|            |                       (A) A product code consisting of 4 digits and a package code consisting of 1 digit for a total NDC length of 10 or 11 digits (5-4-1 or 6-4-1), or                                                                                                                                      |
|            |                       (B) A product code consisting of 3 digits and a package code consisting of 2 digits for a total NDC length of 10 or 11 digits (5-3-2 or 6-3-2).                                                                                                                                        |
| 2002-06-03 | (2) The following combinations of labeler code, product code and package code character lengths are permissible:                                                                                                                                                                                             |
|            |                       (i) If a labeler code is either 5 or 6 digits in length, it may be combined with:                                                                                                                                                                                                      |
|            |                       (A) A product code consisting of 4 digits and a package code consisting of 1 digit for a total NDC length of 10 or 11 digits (5-4-1 or 6-4-1), or                                                                                                                                      |
|            |                       (B) A product code consisting of 3 digits and a package code consisting of 2 digits for a total NDC length of 10 or 11 digits (5-3-2 or 6-3-2).                                                                                                                                        |
| 2018-06-01 | (b) Registrants must review and update their drug listing information each June and December.                                                                                                                                                                                                                |
| 2037-05-01 | Failure to comply with &#167;&#8201;207.37 may also constitute misbranding.                                                                                                                                                                                                                                  |


